Cargando…
Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates
Antibody—drug conjugates (ADCs) play important roles in tumor therapy. However, traditional ADCs are limited by the extremely large molecular weight of the antibody molecules, which results in low permeability into solid tumors. The use of small ADCs may be expected to alleviate this problem, but th...
Autores principales: | Xu, Keyuan, Han, Jiani, Yang, Liu, Cao, Li, Li, Shuang, Hong, Zhangyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342105/ https://www.ncbi.nlm.nih.gov/pubmed/37446189 http://dx.doi.org/10.3390/ijms241311011 |
Ejemplares similares
-
PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates
por: Li, Qiyu, et al.
Publicado: (2021) -
A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy
por: Xing, Yutong, et al.
Publicado: (2021) -
Methods for site-specific drug conjugation to antibodies
por: Behrens, Christopher R, et al.
Publicado: (2014) -
Site-specific antibody drug conjugates for cancer therapy
por: Panowski, Siler, et al.
Publicado: (2013) -
Current Status: Site-Specific Antibody Drug Conjugates
por: Schumacher, Dominik, et al.
Publicado: (2016)